Equitable Trust Co. Decreases Stock Holdings in DaVita Inc. (NYSE:DVA)

Equitable Trust Co. lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 4.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,106 shares of the company’s stock after selling 1,669 shares during the quarter. Equitable Trust Co.’s holdings in DaVita were worth $5,549,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Transcendent Capital Group LLC purchased a new stake in shares of DaVita during the 3rd quarter valued at about $25,000. Blue Trust Inc. grew its stake in shares of DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after acquiring an additional 119 shares during the period. Quarry LP bought a new position in shares of DaVita during the 3rd quarter valued at approximately $60,000. Versant Capital Management Inc grew its stake in shares of DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after acquiring an additional 169 shares during the period. Finally, Wingate Wealth Advisors Inc. bought a new position in shares of DaVita during the 4th quarter valued at approximately $82,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 0.8 %

DVA stock opened at $173.45 on Monday. DaVita Inc. has a 1-year low of $108.76 and a 1-year high of $179.60. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market capitalization of $14.22 billion, a price-to-earnings ratio of 18.71, a PEG ratio of 0.84 and a beta of 0.94. The business has a 50 day simple moving average of $160.59 and a two-hundred day simple moving average of $156.53.

Wall Street Analyst Weigh In

Separately, Barclays boosted their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.